BCL2L1 and myelodysplastic syndrome: Evaluation of the BCL2 and BCLXL promoter regions of the patient samples revealed hypomethylation in the ASXL1 mutant samples (MDS 1–7) compared to the wild-type samples (MDS 8–16) (Fig. 4E), consistent with the overexpression of BCL2 seen in ASXL1 mutant samples.